Literature DB >> 18562203

A possible link between astrocyte activation and tau nitration in Alzheimer's disease.

Juan F Reyes1, Matthew R Reynolds, Peleg M Horowitz, Yifan Fu, Angela L Guillozet-Bongaarts, Robert Berry, Lester I Binder.   

Abstract

Alzheimer's disease (AD) pathology has been characterized, in part, by the self-assembly of the tau molecule into neurofibrillary tangles (NFT). While different post-translational modifications have been identified that accelerate tau aggregation, nitration at tyrosine residues prevents or slows tau filament formation in vitro. Of the five tyrosine residues within the molecule, nitration at the first tyrosine residue (Tyr 18) results in a profound inhibition of filament self-assembly. To determine whether nitration at Tyr 18 occurs in AD pathology, monoclonal antibodies were raised against a synthetic tau peptide nitrated at Tyr 18. A clone, termed Tau-nY18, reacts specifically with tau proteins nitrated at Tyr 18 and fails to cross-react with other nitrated tyrosine residues spanning the length of the molecule or with other proteins known to be nitrated in neurodegenerative diseases. In situ, Tau-nY18 sparsely labels the neuronal pathological hallmarks of the disease, including NFT and dystrophic neurites. Surprisingly however, Tau-nY18 robustly labels nitrated tau within activated, GFAP positive astrocytes intimately associated with amyloid plaques. Furthermore, this antibody detects nitrated tau in soluble preparations from both severe AD brains (Braak stage V, VI) and age-matched controls. Collectively, these findings suggest that nitration at Tyr 18 may be linked to astrocyte activation, an early event associated with amyloid plaque formation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562203      PMCID: PMC2766349          DOI: 10.1016/j.nbd.2008.04.005

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  63 in total

1.  The primary structure and heterogeneity of tau protein from mouse brain.

Authors:  G Lee; N Cowan; M Kirschner
Journal:  Science       Date:  1988-01-15       Impact factor: 47.728

2.  Altered protein tyrosine phosphorylation in Alzheimer's disease.

Authors:  I P Shapiro; E Masliah; T Saitoh
Journal:  J Neurochem       Date:  1991-04       Impact factor: 5.372

3.  Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues.

Authors:  R W Shin; T Iwaki; T Kitamoto; J Tateishi
Journal:  Lab Invest       Date:  1991-05       Impact factor: 5.662

Review 4.  Neuropathological stageing of Alzheimer-related changes.

Authors:  H Braak; E Braak
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

5.  Tau protein immunoreactivity in dementia of the Alzheimer type: II. Electron microscopy and pathogenetic implications. Effects of fixation on the morphology of the Alzheimer's abnormal filaments.

Authors:  S C Papasozomenos
Journal:  Lab Invest       Date:  1989-03       Impact factor: 5.662

6.  Tau protein immunoreactivity in dementia of the Alzheimer type. I. Morphology, evolution, distribution, and pathogenetic implications.

Authors:  S C Papasozomenos
Journal:  Lab Invest       Date:  1989-01       Impact factor: 5.662

7.  Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains.

Authors:  A Himmler; D Drechsel; M W Kirschner; D W Martin
Journal:  Mol Cell Biol       Date:  1989-04       Impact factor: 4.272

8.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

9.  Alz-50 antibody recognizes Alzheimer-related neuronal changes.

Authors:  B T Hyman; G W Van Hoesen; B L Wolozin; P Davies; L J Kromer; A R Damasio
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

10.  The distribution of tau in the mammalian central nervous system.

Authors:  L I Binder; A Frankfurter; L I Rebhun
Journal:  J Cell Biol       Date:  1985-10       Impact factor: 10.539

View more
  30 in total

1.  Tyrosine nitration within the proline-rich region of Tau in Alzheimer's disease.

Authors:  Juan F Reyes; Yifan Fu; Laurel Vana; Nicholas M Kanaan; Lester I Binder
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  Factors influencing protein tyrosine nitration--structure-based predictive models.

Authors:  Alexander S Bayden; Vasily A Yakovlev; Paul R Graves; Ross B Mikkelsen; Glen E Kellogg
Journal:  Free Radic Biol Med       Date:  2010-12-21       Impact factor: 7.376

Review 3.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

4.  Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau-Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers.

Authors:  Richard Rubenstein; Binggong Chang; John K Yue; Allen Chiu; Ethan A Winkler; Ava M Puccio; Ramon Diaz-Arrastia; Esther L Yuh; Pratik Mukherjee; Alex B Valadka; Wayne A Gordon; David O Okonkwo; Peter Davies; Sanjeev Agarwal; Fan Lin; George Sarkis; Hamad Yadikar; Zhihui Yang; Geoffrey T Manley; Kevin K W Wang; Shelly R Cooper; Kristen Dams-O'Connor; Allison J Borrasso; Tomoo Inoue; Andrew I R Maas; David K Menon; David M Schnyer; Mary J Vassar
Journal:  JAMA Neurol       Date:  2017-09-01       Impact factor: 18.302

5.  Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases.

Authors:  Nicholas M Kanaan; Gerardo A Morfini; Nichole E LaPointe; Gustavo F Pigino; Kristina R Patterson; Yuyu Song; Athena Andreadis; Yifan Fu; Scott T Brady; Lester I Binder
Journal:  J Neurosci       Date:  2011-07-06       Impact factor: 6.167

Review 6.  Targeting innate immunity for neurodegenerative disorders of the central nervous system.

Authors:  Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik
Journal:  J Neurochem       Date:  2016-09       Impact factor: 5.372

7.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

Review 8.  Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs).

Authors:  Francois-Xavier Theillet; Andres Binolfi; Tamara Frembgen-Kesner; Karan Hingorani; Mohona Sarkar; Ciara Kyne; Conggang Li; Peter B Crowley; Lila Gierasch; Gary J Pielak; Adrian H Elcock; Anne Gershenson; Philipp Selenko
Journal:  Chem Rev       Date:  2014-06-05       Impact factor: 60.622

9.  Caspase activation in transgenic mice with Alzheimer-like pathology: results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh.

Authors:  Troy T Rohn; Polina Kokoulina; Cody R Eaton; Wayne W Poon
Journal:  Int J Clin Exp Med       Date:  2009-11-05

10.  Bioimaging of peroxynitrite in MCF-7 cells by a new fluorescent probe rhodamine B phenyl hydrazide.

Authors:  Gopi Ambikapathi; Suresh Kumar Kempahanumakkagari; Babu Ramappa Lamani; Devaraju Kuramkote Shivanna; Harish Bodagur Maregowda; Anushree Gupta; Pandurangappa Malingappa
Journal:  J Fluoresc       Date:  2013-03-12       Impact factor: 2.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.